Weitang

Weitang, formerly known as Boyibang, operated as a digital health entity with a specific focus on the diabetes management sector. The company was established in 2012 and was headquartered in Shanghai, China. Weitang's business model revolved around providing a comprehensive digital platform designed for both individuals with diabetes and their healthcare providers.

The core of Weitang's offering was a mobile and online application that enabled users to meticulously track crucial health data. This included monitoring blood sugar levels, logging food consumption, recording physical exercise, and managing medication schedules. The platform's objective was to empower patients with tools for better self-management and to provide clinicians with valuable data to support treatment. A clinical study highlighted the application's efficacy, demonstrating that its use led to significant improvements in key health markers like HbA1c and blood glucose, as well as enhanced patient knowledge and self-care practices.

The company secured capital to support its operations, including a Series A funding round of $5 million in September 2014, followed by a subsequent Series B round. Despite its promising start and the clinical validation of its platform, publicly available investment data indicates the company is now out of business.

Keywords: diabetes management, digital health, HealthTech, mobile health, chronic disease management, blood glucose monitoring, patient engagement, clinical decision support, telehealth, Weitang, Welltang, Boyibang, China digital health, diabetes app, remote patient monitoring, healthcare software, medical technology, Series A, Series B, venture capital